ALT Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

ALT blood test

Alanine aminotransferase. Also called: SGPT, Alanine transaminase, GPT

Biomarker guideLast updated: October 29, 2026

ALT is a liver enzyme that leaks into the blood when liver cells are damaged. It is the most liver-specific of the routine liver tests, but weight, alcohol, medications and hard exercise can all raise it.

LOINC 1742-6Digestive

At a glance

What it measuresAlanine aminotransferase, an enzyme concentrated in liver cells that spills into the blood when they are injured.
SampleBlood (serum or heparin plasma). Neither Labcorp nor Quest lists a fasting requirement.
Typical adult rangeLabcorp: below 33 U/L (women) and below 45 U/L (men). Quest, age 20 and over: 6-29 U/L (women) and 9-46 U/L (men).
Common reasons it reads highFatty liver, alcohol, viral hepatitis, medications such as statins, heavy exercise or muscle injury, obesity, celiac disease.
Peptides that move itLowered in fatty-liver trials by Semaglutide, Tirzepatide, Survodutide and Mazdutide. Label-listed rises with Pasireotide, Degarelix and Triptorelin.
Lab codeLOINC 1742-6 (Labcorp 001545, Quest 823)

What is ALT?

Alanine aminotransferase (ALT, formerly called SGPT) is an enzyme that shuffles nitrogen between amino acids, part of protein metabolism and of making new glucose. Its activity is highest in the liver, and inside liver cells it sits in the cytoplasm, so it leaks into the blood when those cells are damaged.

It is part of every routine liver panel. Labcorp describes ALT as more sensitive for injury to liver cells than for blocked bile flow, and more specific for liver injury than AST.

Sources: [1] [2]

How it is made and regulated

Where it is made

Activity is highest in the liver, followed by kidney, heart muscle, skeletal muscle, pancreas, spleen, lung and red blood cells. Unlike AST, ALT has no mitochondrial form, and in every tissue except the liver its activity is much lower than AST's.

Sources: [1]

What controls it

Blood ALT mostly reflects how many liver cells are leaking it. In healthy blood donors it rose with body mass index and with signs of abnormal fat or sugar metabolism, and Labcorp notes that ALT is increased with obesity.

Sources: [3] [2]

How it travels in the blood

Both aminotransferases use vitamin B6 (pyridoxal phosphate) as a co-factor. Some lab methods add it to the reagent, which matters for people who may be low in B6, such as heavy drinkers, older adults and people with cancer.

Sources: [4] [5]

How long it lasts

ALT stays in the blood longer than AST: about 36 hours, against about 18 hours for AST. That difference shapes the AST/ALT ratio over the course of an illness.

Sources: [4]

What it does

Its clinical value is as a marker of liver-cell injury. Several studies have linked a raised ALT with higher liver-related death, and the ACG guideline says levels above the healthy range should be assessed.

Sources: [6]

Reference ranges

Labcorp publishes upper limits only, from its own study of more than 260,000 people; Quest gives a low-high range for each age and sex. Men run higher than women in both. Use the range printed on your report.

Labcorp (test 001545)

Method: Kinetic. Labcorp test page (retrieved October 29, 2026).

GroupRange (U/L)
Females, 18 years and olderBelow 33
Males, 18 years and olderBelow 45
Children and teens
GroupRange (U/L)
Females, 0 to 11 yearsBelow 29
Females, 12 to 17 yearsBelow 25
Males, 0 to 11 yearsBelow 30
Males, 12 to 17 yearsBelow 31

From Labcorp's ALT reference-interval document (internal study of more than 260,000 male and female subjects). Upper limits only. Labcorp's 2022 sample report prints the adult male interval as 0-44 IU/L.

Quest Diagnostics (test 823)

Method: Spectrophotometry (SP). Quest Diagnostics test page (retrieved October 29, 2026).

GroupRange (U/L)
Males, 20 years and older9-46
Females, 20 years and older6-29
Children and teens
GroupRange (U/L)
Males, under 28 days3-25
Females, under 28 days3-25
Males, 28 days to 11 months4-35
Females, 28 days to 11 months3-30
Males, 1 to 3 years5-30
Females, 1 to 3 years5-30
Males, 4 to 12 years8-30
Females, 4 to 12 years8-24
Males, 13 to 15 years7-32
Females, 13 to 15 years6-19
Males, 16 to 19 years8-46
Females, 16 to 19 years5-32

Ranges as shown for Quest's East region. Quest notes that people taking sulfasalazine may get falsely low results with this assay.

Labcorp's ALT test page does not print a range; the Labcorp intervals come from its ALT reference-interval document, and its 2022 sample report prints 0-44 IU/L for an adult man. Quest's ranges are for its East region.

Units: Labcorp prints IU/L and Quest U/L; both are enzyme units per liter. Some labs outside the US report nkat/L: 30 U/L is 500 nkat/L. [3]

Sources: [7] [8] [9]

Is there an "optimal" range?

Many experts think the usual ALT limits are too high, because the groups used to set them included people with unrecognized fatty liver or hepatitis.

Healthy limits are lower than lab limits

Men 30 U/L, women 19 U/L

Prati and colleagues, 6,835 first-time blood donors in Milan

Limits computed from the donors at lowest risk were lower than the limits then in use (40 U/L for men, 30 U/L for women) and picked up more people with hepatitis C in the blood (sensitivity 76.3% vs 55%).

Sources: [3]

Guideline healthy range

Men 29-33 U/L, women 19-25 U/L

American College of Gastroenterology clinical guideline (2017)

Calls this the true healthy normal ALT and says levels above it should be assessed, because a raised ALT is linked with higher liver-related death.

Sources: [6]

Lower cut-offs flag many people

Best cut-offs 29 U/L for men, 22 U/L for women

US NHANES 1999-2008 (259 adults with hepatitis C RNA, 3,747 at low risk)

These cut-offs separated hepatitis C from low-risk adults best, but applied to the whole population they would label 36.4% of men and 28.3% of women abnormal.

Sources: [10]

Lab limits stay higher

Below 45 U/L for men, below 33 U/L for women

Labcorp internal study (more than 260,000 subjects)

Labcorp sets its adult limits from its own population and cites the National Academy of Clinical Biochemistry view that 45 U/L is a clinically useful upper limit in men.

Sources: [7]

What raises it

FactorHowHow much
Fatty liver and excess weightConditionALT rises with body mass index and with abnormal fat or sugar metabolism; Labcorp notes that ALT is increased with obesity. Fatty liver disease is among the commonest causes of a mild rise.No published magnitude [3] [2] [7]
AlcoholLifestyleAlcohol injures liver cells, but ALT rises less than AST in alcohol-related liver disease. Most heavy drinkers without severe liver disease have an AST/ALT ratio of 1 or below; a high ratio points to advanced disease.AST/ALT ratio of 1.0 or below in 64% of 313 patients admitted for alcohol withdrawal; 2 or above in 69% of patients with alcohol-related cirrhosis [2] [11]
Viral hepatitisConditionHepatitis viruses inflame liver cells. In acute viral hepatitis the transaminases may rise 10 times or more above their upper limits; chronic hepatitis B or C usually gives a mild rise.In chronic kidney disease, ALT averaged 32.9 IU/L with hepatitis C antibodies vs 17.7 IU/L without [12] [7] [13]
MedicationsMedicationMany drugs raise ALT, including phenytoin, heparin and statins. With statins the rise is usually symptom-free, dose-related and reversible, and often settles even if treatment continues.Statins: usually under 3 times the upper limit of normal [2] [14] [15]
Heavy exercise and muscle injuryLifestyleDamaged muscle releases ALT as well as AST and CK. Labcorp lists rhabdomyolysis, polymyositis and trauma to muscle as causes; a high CK points to muscle rather than liver.Raised for at least 7 days after a 1-hour weightlifting session in 15 healthy men [16] [2] [17]
Celiac diseaseConditionUntreated celiac disease often disturbs liver tests; ALT improved after 6 months on a gluten-free diet.ALT high in 7.6% of 132 children and teens at diagnosis [18]
Hemolyzed samplePhysiologyRed cells contain about six times as much ALT as serum, so a grossly hemolyzed sample can give a spurious result.No published magnitude [2]
Peptide drugs with label-listed risesPeptideSeveral peptide drugs list ALT rises on their labels, including pasireotide and the GnRH analogs. See the peptide table below.Pasireotide: ALT increased in 17 of 162 patients (10%) in a Cushing disease trial [19]

What lowers it

FactorHowHow much
Chronic kidney disease and dialysisConditionPeople with kidney failure have lower aminotransferase levels than healthy people, and dialysis patients lower still, which can hide liver injury.Mean 17.5 vs 21.7 IU/L in people with chronic kidney failure (no viral hepatitis) vs healthy people [13] [20]
Vitamin B6 deficiencyNutritionALT needs vitamin B6 as a co-factor, and subnormal aminotransferase levels are seen in B6 deficiency.No published magnitude [20] [4]
SulfasalazineMedicationThe assay manufacturer warns that people taking sulfasalazine may get falsely low ALT results with this method.No published magnitude [9]
Gluten-free diet in celiac diseaseNutritionA fall in ALT was the most pronounced liver-test response to a gluten-free diet in children with celiac disease.No published magnitude [18]
Fatty-liver treatment with GLP-1-based peptidesPeptideWeight loss and less liver fat bring ALT down. See the peptide table below.Survodutide 6.0 mg weekly: ALT -36.8% vs -11.0% with placebo at 48 weeks [21]

Peptides that affect ALT

How each peptide in our library has been shown to affect ALT, strongest evidence first. Falls mostly come from fatty-liver trials; rises mostly come from drug labels. "No clear effect" means ALT was measured and did not change; "Unclear" means the results conflict.

PeptideEffect on ALTSize of effectEvidence
AnamorelinRaisesJapanese post-marketing surveillance (N = 6016): treatment-related hepatic impairment in 1.2% (grade ≥3 in 0.3%); the most common was ALT increasedAn uncommon liver-enzyme rise in cancer patients taking anamorelin; severe cases were rare. [22]Human trials
BivalirudinRaisesChinese patients having coronary angiography: ALT higher after the procedure than at baseline with bivalirudin (p = 0.005); small absolute changeA small ALT rise around coronary angiography; the authors suggest heparin may cause less liver change. [23]Human trials
Polymyxin BRaisesRetrospective cohort, carbapenem-resistant Gram-negative infections: ALT increased in 5/50 (10.0%) on polymyxin B vs 4/30 (13.3%) on colistin sulfate (p = 0.722)An uncontrolled cohort of very ill patients; no untreated comparison group. [24]Human trials
CotadutideLowersGreater ALT reductions than placebo with 200 µg (P = 0.009) and 300 µg (P = 0.003) daily after 54 weeks in adults with type 2 diabetes and overweight or obesityPhase 2b trial; the drop was largest in people who started with the highest ALT. [25]Human trials
Erythropoietin (EPO)LowersALT lower with 30,000 U before liver clamping and at the end of surgery than with hydrocortisone on day 0 (P = 0.020) and day 1 (P = 0.004); 27 liver-surgery patientsProtection against liver injury from blood-flow clamping during surgery, not an effect in healthy people. [26]Human trials
ExenatideLowersALT lower than with intensive insulin (p < 0.001) after 12 weeks in 60 newly diagnosed type 2 diabetes patients with obesity and NAFLD with raised liver enzymesSeen in people with fatty liver and high enzymes; the fall tracked weight loss. [27]Human trials
Human Relaxin-2LowersRELAX-AHF (acute heart failure), IV serelaxin: ALT among hepatic-damage markers improved vs placebo through day 14; no figure in abstractIn acute heart failure, serelaxin limited the rise in liver-damage markers including ALT. The abstract gives no ALT figures. [28]Human trials
LeptinLowersMetreleptin in 55 people with lipodystrophy: baseline ALT 100 ± 120 U/L fell by 45 ± 19 U/L over 3 yearsSeen in leptin-deficient lipodystrophy with fatty liver disease; not studied in people with normal leptin. [29] [30]Human trials
MazdutideLowersPhase 2, 248 Chinese adults with overweight/obesity, 24 weeks: ALT -29.0%, -25.9%, -22.6% (3, 4.5, 6 mg) vs -3.4% placeboALT fell alongside weight loss; many participants had fatty liver at baseline. [31]Human trials
SemaglutideLowersMeta-analysis of randomized trials in people with or at risk of MASH: ALT WMD -5.55 U/L (95% CI -9.21 to -1.89). Wegovy label: pediatric trial ALT >=5x ULN in 4 (3%) vs 0% placeboLowers ALT in fatty-liver disease. The Wegovy label notes ALT rises of 5x the upper limit in 3% of treated adolescents, some with confounders such as gallstones. [32] [33]Human trials
SurvodutideLowersSYNCHRONIZE-MASLD phase 3, obesity + MASLD, 6.0 mg weekly, 48 weeks: ALT -36.8% vs -11.0% placeboLowered ALT in adults with obesity and fatty liver disease. [21]Human trials
Thymosin Alpha-1LowersHBeAg-positive chronic hepatitis B: lamivudine + thymosin alpha-1 vs lamivudine alone, meta-analysis of 8 trials (583 patients): ALT normalization 80.2% vs 68.8% (P=0.01)In chronic hepatitis B, adding thymosin alpha-1 normalized ALT more often, reflecting less viral liver inflammation. [34]Human trials
TirzepatideLowersSYNERGY-NASH phase 2 (biopsy-proven MASH) pooled in a meta-analysis: ALT mean difference -30.90% vs placebo (P<0.00001)Lowered ALT in adults with MASH (fatty liver inflammation). Isolated case reports of liver injury exist. [35]Human trials
CarnosineNo clear effectNEAT RCT: carnosine 2 g/day vs placebo for 12 weeks; ALT measured (Quest) with no effect on liver functionOral carnosine did not change ALT in a placebo-controlled trial. [36]Human trials
ColistinNo clear effectPatients with blood cancers treated with colistin sulfate for resistant infections: ALT did not change significantly (p > 0.1)Colistin is hard on the kidneys but did not move liver enzymes in this cohort. [37]Human trials
EnfuvirtideNo clear effectALT 22.27 to 23.64 U/L (p = 0.192) with 90 mg twice daily for 7 days in 12 healthy men (crossover vs placebo)No ALT change in healthy volunteers; LiverTox reports no link to aminotransferase rises in treatment. [38] [39]Human trials
LiraglutideNo clear effectMeta-analysis of 5 RCTs, 180 people with biopsy-proven NASH: ALT mean difference 2.66 IU/L (-1.56 to 6.87), p = 0.22In NASH trials, liraglutide did not change ALT significantly versus control. [40]Human trials
RetatrutideNo clear effectMASLD substudy (obesity, liver fat >=10%), 48 weeks: baseline ALT normal (29-36 IU/L); 4 mg arm -30.3% at week 24 (P=0.044 vs placebo) but no consistent change across doses and time pointsIn people with fatty liver and normal starting ALT, retatrutide did not change ALT consistently versus placebo even though liver fat fell. [41]Human trials
TesamorelinNo clear effectHIV with fatty liver, 2 mg daily for 12 months (61 enrolled): no significant ALT change overall; in people starting above 30 U/L, ALT fell by 29 U/L vs placebo (95% CI -55 to -3, P = 0.03)Overall ALT did not change versus placebo; the fall was confined to people who started with raised ALT. In earlier phase III data, ALT fell more in people whose belly fat dropped. [42] [43]Human trials
CetrorelixRaisesControlled ovarian stimulation trials: ALT, AST, GGT or alkaline phosphatase elevations in 1-2% of patients, up to 3 times the upper limit of normalAn uncommon, mild liver-enzyme rise listed on the FDA label; its clinical significance was not determined. [44]FDA label
DaptomycinRaises"Alanine aminotransferase increased" listed among reactions possibly or probably drug-related in adult skin-infection trials; "abnormal liver function tests" 3.0% vs 1.6% with comparatorAn uncommon label-listed lab abnormality; muscle enzyme (CPK) rises are the main lab concern with daptomycin. [45]FDA label
DegarelixRaisesTransaminase and GGT increases in 10% vs 5% with leuprolide in the pivotal trial; in the extension study grade 1/2 transaminase rises in 47% and grade 3 in 1% (men with prostate cancer)Mostly mild rises in liver enzymes during long-term treatment. [46]FDA label
GoserelinRaisesALT elevations reported in under 1% of women given the 3.6 mg implant; the label says causality was not establishedRare and not proven to be caused by goserelin. [47]FDA label
IGF-1 (Insulin-Like Growth Factor 1)RaisesIncrelex (mecasermin) trials in children with primary IGF-1 deficiency: occasional ALT elevations during treatment; no frequency givenLabel notes occasional ALT rises during treatment in children. [48]FDA label
LeuprolideRaisesLupron Depot 30 mg 4-month trials (prostate cancer): increased liver function tests (ALT, AST, GGTP, LDH) recorded in at least 5% of patientsListed among lab abnormalities in men with advanced prostate cancer, where disease and other treatments make attribution hard. [49] [50]FDA label
OctreotideRaisesMycapssa label, postmarketing octreotide reports: "increased liver enzymes" (no frequency; test not specified)Postmarketing reports of raised liver enzymes; the label gives no rate and does not name ALT separately, so the entry is shown for both ALT and AST. [51]FDA label
PasireotideRaisesPhase III Cushing disease trial (162 patients, 0.6-0.9 mg SC twice daily): ALT increased in 17 (10%); 5% had ALT or AST >3x ULN; mean rises returned to baseline by month 4Usually transient; the label asks for liver tests after 1-2 weeks, monthly for 3 months, then every 6 months. [19]FDA label
TriptorelinRaisesTrelstar trials (prostate cancer): SGPT increases in >=10% of patients on 11.25 mg (Day 253) and hepatic transaminase rises on 22.5 mg, mostly mild to moderate; none with 3.75 mgLabel lists mild-to-moderate ALT rises with the 3- and 6-month depot doses in men with prostate cancer. [52]FDA label
PT-141 (Bremelanotide)No clear effectBremelanotide trials: no imbalance in transaminase outliers vs placebo; one acute hepatitis case (transaminases >40x ULN) after 10 doses in the open-label extensionNo overall transaminase signal, but one unexplained hepatitis case is in the label. [53]FDA label
AdiponectinLowersRats with hepatic ischemia-reperfusion, recombinant adiponectin: ALT 1239.2 ± 102.2 vs 1942.4 ± 154.4 U/L at 6 h (P < 0.05)Recombinant adiponectin reduced liver injury in a rat ischemia-reperfusion model. No human dosing data. [54]Animal studies
Adrenocorticotropic Hormone (ACTH)LowersRats with TNF-induced injury: ACTH gel 10 IU/kg lowered serum ALT (values shown only in figures)Lowered the liver-enzyme rise in a rat inflammatory injury model. No human liver data. [55]Animal studies
Alpha-Melanocyte-Stimulating Hormone (α-MSH)LowersMice given acetaminophen (150 mg/kg): alpha-MSH 1.5 × 10^-6 mol/kg i.p. lowered plasma transaminases at 24 h; the highest dose tested (3 × 10^-6 mol/kg) did not protectIn a mouse acetaminophen liver-injury model, alpha-MSH lowered ALT at one mid-range dose. No human data. [56]Animal studies
BPC-157LowersMice with radiation-induced liver injury (12 Gy), oral BPC-157: lower plasma ALT; similar findings in other rat liver-injury modelsLowered ALT in rodent liver-injury models. No human data on ALT. [57]Animal studies
GalaninLowersSerum ALT reduced with 8 µg/100 g/day s.c. for 5 weeks in mice fed a high-fat, high-cholesterol diet (NASH model)Mouse fatty-liver model only. [58]Animal studies
GHRP-2LowersBlunted the LPS-induced rise in serum transaminases with 100 µg/kg i.p. in rats with endotoxemiaRat endotoxin model of liver injury only. [59]Animal studies
SelankLowersMale Wistar rats, 1000 ug/kg intraperitoneally 15 min before acute restraint stress: serum aminotransferases reducedRat stress study only: the highest dose lowered stress-raised aminotransferases. No human data. [60]Animal studies
VasopressinLowersPigs with fecal peritonitis, AVP 0.06 U/kg/h added to noradrenaline vs noradrenaline alone, 24 h (n=24): rise in serum transaminases bluntedAnimal sepsis study: compared with noradrenaline alone, vasopressin limited the rise in liver enzymes. [61]Animal studies
AdrenomedullinNo clear effectRats with hepatic ischemia-reperfusion: ALT 346.8 with adrenomedullin alone vs 352.4 IU/L with vehicle; only AM combined with its binding protein AMBP-1 lowered ALT (by 31%)Adrenomedullin alone did not lower ALT in rats; the drop needed its binding protein AMBP-1 given with it. [62]Animal studies
SemaxUnclearRats, 5-450 ug/kg intraperitoneally: normalized serum ALT in chronic foot-shock stress, but under immobilization stress ALT fell at 5-50 ug/kg and rose at 450 ug/kgRat stress studies only, with dose-dependent results in both directions. No human data. [63] [64]Animal studies

What high or low results can mean

A high result

A high ALT usually means liver cells are being damaged, most often from fatty liver, alcohol, viral hepatitis or medications. Heavy exercise and muscle injury can raise it too.

  • Fatty liver disease, often with excess weight
  • Alcohol
  • Viral hepatitis
  • Medications, herbal products and supplements
  • Heavy exercise or muscle injury
  • Less common: hemochromatosis, autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, celiac disease

Next step: Discuss it with a clinician. Typical first steps are repeating the test, reviewing medicines and supplements, and checking for hepatitis B and C, fatty liver and alcohol use. If you trained hard in the days before the test, a repeat after a rest is reasonable.

Sources: [6] [7] [16]

A low result

A low ALT is rarely a concern, but it can go with vitamin B6 deficiency or chronic kidney disease.

  • Vitamin B6 deficiency
  • Chronic kidney disease or dialysis
  • Sulfasalazine (falsely low with some assays)

Next step: Usually no action is needed. In kidney failure a "normal" ALT can hide liver injury, so mention any liver risk factors to your clinician.

Sources: [20] [13] [9]

How the test works

SampleSerum (preferred) or lithium-heparin plasma at Labcorp, which does not accept oxalate, EDTA or citrate plasma and asks for the serum to be separated within 45 minutes. Quest prefers 1 mL of serum and also accepts sodium or lithium heparin plasma.
FastingNeither Labcorp nor Quest lists a fasting requirement for ALT.
TimingTime of day makes little difference: in US national survey data, morning and afternoon results were essentially the same (women 19.1 vs 19.6 IU/L). Hard exercise, especially weightlifting, can raise ALT for at least 7 days, so avoid it before the test.
Lab differencesLabcorp uses a kinetic method and Quest spectrophotometry. Methods with and without added vitamin B6 (pyridoxal phosphate) can differ in people low in B6; LOINC codes the B6 method separately (1743-4). Gross hemolysis can give spurious results.
RetestingALT varies a lot from week to week in the same person: published within-person variation ranges from 11.1% to 58.1% (median 18.0%). A single borderline result is usually repeated before anything else is done.
Labcorp order code001545: Alanine Aminotransferase (ALT/SGPT)
Quest Diagnostics order code823: Alanine Aminotransferase (ALT)
LOINC codes
  • 1742-6: Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
  • 1743-4: Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma by With P-5'-P (method with added vitamin B6 (pyridoxal 5'-phosphate))
  • 76625-3: Alanine aminotransferase [Enzymatic activity/volume] in Blood (whole blood)
LOINC 1742-6 on loinc.org

Sources: [2] [9] [65] [66] [16] [4] [67]

History

Transaminase blood tests were among the first enzyme tests in clinical medicine. AST (then SGOT) came first, for heart attacks; ALT (then SGPT) followed in 1956 as a test for liver disease.

  1. 1955Karmen, Wróblewski and LaDue describe transaminase activity in human blood. [68]
  2. 1956LaDue and Wróblewski publish a preliminary report on serum glutamic pyruvic transaminase (SGP-T, now ALT) in liver disease, and a second paper on SGPT in heart disease with liver involvement. [69] [70]
  3. 1957De Ritis, Coltorti and Giusti publish an enzyme test for diagnosing viral hepatitis from serum transaminase activities, the origin of the AST/ALT "De Ritis ratio". [71] [4]
  4. 2002The IFCC publishes its primary reference procedure for measuring ALT at 37 °C. [72]
  5. 2002Prati and colleagues propose lower healthy limits for ALT (30 U/L for men, 19 U/L for women) from low-risk blood donors. [3]
  6. 2017The American College of Gastroenterology guideline puts healthy ALT at 29-33 U/L for men and 19-25 U/L for women. [6]

FAQ

Do I need to fast before an ALT test?

Neither Labcorp nor Quest lists a fasting requirement for ALT. Time of day also makes little difference: in US national survey data, morning and afternoon results were almost the same.

Sources: [2] [9] [66]

Can exercise raise ALT?

Yes. In 15 healthy men, one hour of weightlifting raised ALT and AST for at least 7 days. Muscle releases these enzymes too, so avoid hard training for several days before a liver test.

Sources: [16] [17]

What is a normal ALT level?

It depends on the lab and your sex. Labcorp's adult limits are below 33 U/L for women and below 45 U/L for men; Quest's adult ranges are 6-29 U/L and 9-46 U/L. The ACG guideline puts truly healthy ALT lower, at 29-33 U/L for men and 19-25 U/L for women.

Sources: [7] [9] [6]

What causes a high ALT?

The common causes are fatty liver, alcohol, viral hepatitis and medications. Less common causes include hemochromatosis, autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency and celiac disease, and muscle injury can raise it as well.

Sources: [6] [7] [2]

How high is too high?

Labcorp's guidance, following the American Gastroenterological Association, calls a rise under 5 times the upper limit mild (typical of fatty liver, chronic hepatitis or medications) and over 15 times severe (acute viral hepatitis, toxins, reduced blood flow to the liver). Any persistent rise is worth discussing with a clinician.

Sources: [7]

What is the difference between ALT and AST?

Both are liver enzymes, but ALT is found mainly in the liver, while AST is also abundant in heart, muscle and red cells, so ALT is more liver-specific. Comparing the two (the AST/ALT ratio) helps: a ratio of 2 or more is typical of advanced alcohol-related liver disease.

Sources: [1] [2] [11] [4]

Can medications or supplements raise ALT?

Yes. Labcorp lists phenytoin and heparin among many drugs that raise ALT. Statins often cause a mild, symptom-free rise, usually under 3 times the upper limit, that is dose-related and often settles without stopping the drug.

Sources: [2] [14] [15]

Can peptides affect ALT?

GLP-1-based peptides lowered ALT in fatty-liver trials: Semaglutide, Tirzepatide, Survodutide and Mazdutide. Labels for Pasireotide, Degarelix, Triptorelin and Leuprolide list ALT rises. Most other peptide data come from animal studies.

Sources: [32] [35] [21] [31] [19] [46] [52] [49]

Can my ALT be normal if I have fatty liver?

Yes. Lab limits were set using groups that included people with unrecognized liver disease, so a result inside the lab range does not rule it out. Lower limits drawn from low-risk donors picked up more people with liver disease.

Sources: [3] [10]

Is a low ALT a problem?

Rarely. Low aminotransferase levels can go with vitamin B6 deficiency or chronic kidney disease. In people on dialysis, low baseline levels can make liver injury harder to spot.

Sources: [20] [13]

Is ALT different in men and women?

Yes, men run higher. Quest's adult range is 9-46 U/L for men and 6-29 U/L for women, and Labcorp's adult limits are below 45 U/L and below 33 U/L.

Sources: [9] [7]

How much does ALT vary between tests?

A lot. Studies of the same people over time report within-person variation from 11.1% to 58.1%, with a median of 18.0%, so a small change between two tests may be noise.

Sources: [67]

References

  1. Aminotransferases. In: Clinical Methods: The History, Physical, and Laboratory Examinations [Internet]. Butterworths; 1990. PMID 21250265
  2. Labcorp. Test 001545: Alanine Aminotransferase (ALT/SGPT). Methodology, use, limitations, specimen requirements and LOINC map. labcorp.com/tests/001545/alanine-aminotransferase-alt-sgpt
  3. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10. PMID 12093239
  4. Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013;34(3):117-30. PMID 24353357
  5. Rossouw JE, Labadarios D, Davis M, et al. Vitamin B6 and aspartate aminotransferase activity in chronic liver disease. S Afr Med J. 1978;53(12):436-8. PMID 675385
  6. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. PMID 27995906
  7. Labcorp. New ALT Reference Intervals for Children and Adults (clinical information document; Labcorp internal study of more than 260,000 subjects). labcorp.com/assets/5286
  8. Labcorp. Sample patient report, test 322000: Comprehensive Metabolic Panel (14), reported 10/31/2022 (printed AST and ALT reference intervals). files.labcorp.com/testmenu-d8/sample_reports/322000.pdf
  9. Quest Diagnostics. Test code 823: Alanine Aminotransferase (ALT). Test directory entry (East region): methodology, specimen, patient preparation, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/823/alanine-aminotransferase-alt?cc=PHP
  10. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2012;55(2):447-54. PMID 21987480
  11. Nyblom H, Berggren U, Balldin J, et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336-9. PMID 15208167
  12. Labcorp. Test 001123: Aspartate Aminotransferase (AST/SGOT). Methodology, use, limitations, specimen requirements and LOINC map. labcorp.com/tests/001123/aspartate-aminotransferase-ast-sgot
  13. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2001;38(5):1009-15. PMID 11684554
  14. Cadranel JF, Seddik M, Loric S, et al. [Statins: hepatotoxicity and monitoring]. Presse Med. 2009;38(5):717-25. PMID 19111435
  15. Calderon RM, Cubeddu LX, Goldberg RB, et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349-56. PMID 20360293
  16. Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65(2):253-9. PMID 17764474
  17. Khatri P, Neupane A, Sapkota SR, et al. Strenuous Exercise-Induced Tremendously Elevated Transaminases Levels in a Healthy Adult: A Diagnostic Dilemma. Case Reports Hepatol. 2021;2021:6653266. PMID 33777462
  18. Saadah OI, Khayat A, Abusharifah O, et al. Liver function changes following the introduction of a gluten-free diet in patients with celiac disease. Clin Exp Hepatol. 2021;7(4):415-421. PMID 35402725
  19. SIGNIFOR (pasireotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
  20. Youssef EM, Wu GY. Subnormal Serum Liver Enzyme Levels: A Review of Pathophysiology and Clinical Significance. J Clin Transl Hepatol. 2024;12(4):428-435. PMID 38638374
  21. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. PMID 42252333
  22. Takayama K, Kojima A, Honda C, et al. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan. Cancer Med. 2024;13(9):e7170. PMID 38693813
  23. Jia Q, Hu J, Ji W, et al. Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention. J Clin Transl Hepatol. 2021;9(4):477-483. PMID 34447676
  24. Wang J, Shah BK, Zhao J, et al. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect Dis. 2023;23(1):351. PMID 37231342
  25. Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021;44(6):1433-1442. PMID 34016612
  26. Kato M, Sawada T, Kita J, et al. Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver. World J Gastroenterol. 2010;16(38):4838-45. PMID 20939113
  27. Shao N, Kuang HY, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(6):521-9. PMID 24823873
  28. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61(2):196-206. PMID 23273292
  29. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922-32. PMID 22068254
  30. Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131-7. PMID 23439261
  31. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289. PMID 38092790
  32. Kan R, Wang S, Meng X, et al. The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials. Diabetol Metab Syndr. 2025;17(1):439. PMID 41286982
  33. WEGOVY (semaglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  34. Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63. PMID 19467157
  35. Zhao S, Tian F, Yu L, et al. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials. Intern Emerg Med. 2026;21(4):1343-1353. PMID 41917519
  36. Baba SP, Amraotkar AR, Hoetker D, et al. Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial. Amino Acids. 2024;56(1):55. PMID 39215872
  37. Wu Y, Jiang S, Li D, et al. Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases. Infect Dis Ther. 2024;13(1):141-154. PMID 38212555
  38. Barroso S, Morén C, González-Segura À, et al. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers. PLoS One. 2019;14(5):e0216712. PMID 31120908
  39. Enfuvirtide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID 31644169
  40. Malik A, Amjad W, Inayat F, et al. The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials. Prz Gastroenterol. 2023;18(1):100-109. PMID 37007754
  41. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523
  42. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038
  43. Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2259. PMID 28832410
  44. CETROTIDE (cetrorelix acetate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  45. Daptomycin for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d750e28d-1353-4671-66a3-ea4e49e81e7b
  46. FIRMAGON (degarelix) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
  47. ZOLADEX (goserelin implant) 3.6 mg, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
  48. INCRELEX (mecasermin) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
  49. LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  50. Leuprolide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID 31643987
  51. MYCAPSSA (octreotide) delayed-release capsules, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d80bc6-bdfb-4908-93e7-aace447c8d1a
  52. TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  53. VYLEESI (bremelanotide injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
  54. Zhang C, Liao Y, Li Q, et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One. 2013;8(6):e66382. PMID 23762489
  55. Si J, Ge Y, Zhuang S, et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int. 2013;83(4):635-46. PMID 23325074
  56. Blagaić V, Houra K, Turcić P, et al. The influence of alpha-, beta-, and gamma-melanocyte stimulating hormone on acetaminophen induced liver lesions in male CBA mice. Molecules. 2010;15(3):1232-41. PMID 20335976
  57. Huang BS, Huang SC, Chen FH, et al. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life Sci. 2022;310:121072. PMID 36228773
  58. He L, Huang C, Wang H, et al. Galanin ameliorates liver inflammation and fibrosis in mice by activating AMPK/ACC signaling and modifying macrophage inflammatory phenotype. Front Immunol. 2023;14:1161676. PMID 37180164
  59. Granado M, Martín AI, López-Menduiña M, et al. GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am J Physiol Endocrinol Metab. 2008;294(1):E131-41. PMID 17986630
  60. Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bull Exp Biol Med. 2017;163(4):415-418. PMID 28853100
  61. Simon F, Giudici R, Scheuerle A, et al. Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. Crit Care. 2009;13(4):R113. PMID 19591694
  62. Yang J, Wu R, Qiang X, et al. Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion. Ann Surg. 2009;249(2):310-7. PMID 19212187
  63. Bobyntsev II, Shepeleva OM, Kryukov AA, et al. [The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress]. Ross Fiziol Zh Im I M Sechenova. 2015;101(2):171-9. PMID 26012109
  64. Bobyntsev I, Kryukov AA, Shepeleva M, et al. [THE EFFECT OF ACTH-(4-7)-PGP PEPTIDE ON LIPID PEROXIDATION IN LIVER AND ACTIVITY OF SERUM TRANSAMINASES IN RATS UNDER ACUTE AND CHRONIC IMMOBILIZATION STRESS CONDITIONS]. Eksp Klin Farmakol. 2015;78(8):18-21. PMID 26591577
  65. LOINC 1742-6: Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/1742-6
  66. Ruhl CE, Everhart JE. Diurnal variation in serum alanine aminotransferase activity in the US population. J Clin Gastroenterol. 2013;47(2):165-73. PMID 23164687
  67. Carobene A, Braga F, Roraas T, et al. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase. Clin Chem Lab Med. 2013;51(10):1997-2007. PMID 24072574
  68. KARMEN A, WROBLEWSKI F, LADUE JS. Transaminase activity in human blood. J Clin Invest. 1955;34(1):126-31. PMID 13221663
  69. LADUE JS, WROBLEWSKI F. Serum glutamic pyruvic transaminase SGP-T in hepatic disease: a preliminary report. Ann Intern Med. 1956;45(5):801-11. PMID 13373188
  70. WROBLEWSKI F, LADUE JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med. 1956;91(4):569-71. PMID 13323003
  71. DE RITIS F, COLTORTI M, GIUSTI G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70-4. PMID 13447217
  72. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40(7):718-24. PMID 12241021

Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.